

Medicines Optimisation Advice Bulletin – Updated June 2024

For the attention of primary and secondary care staff involved in patient care

Tirzepatide for treating Type 2 diabetes

NICE recently published [TA924 - Tirzepatide for treating type 2 diabetes](#). TAG have commissioned this as **ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation**. Please see [Netformulary](#) entry for further information.

Tirzepatide for managing overweight and obesity

On 8th November 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) authorised a new indication for [tirzepatide](#) - **weight loss and weight management in adults aged 18 and over**. The medicine is to be used together with a reduced-calorie diet and increased physical activity.

NICE have not yet made a recommendation.

Publication of a NICE Technology Appraisal is expected in October 2024. Draft guidance can be viewed [here](#). Local commissioning arrangements will then be considered. In the meantime, there should be **no prescribing of Tirzepatide in primary or secondary care for weight management**.

Please email the medicines optimisation team with 'TAG' in the subject line if you have any further questions or comments - nwicb.medsqueries@nhs.net.

Many thanks for your support.

Sent on behalf of the Norfolk and Waveney Therapeutics Advisory Group